The 
Reflex sympathetic dystrophy (RSD) has been defined as a sympathetically mediated pain syndrome. 1 This active, progressive process is characterized by pain, edema, and autonomic dysfunction, often exacerbated by emotional factors. Swelling is the most constant physical finding, which if not treated early is often followed by the rapid onset of stiffness. Secondary signs, which are variably present, include osseous demineralization, movement disorder, skin discoloration, palmar fibrosis, hyperhydrosis, and sudomotor, temperature, trophic, and vasomotor changes. 1 Clinicians experienced in the treatment of RSD agree that early diagnosis and treatment are of paramount importance.
Pathophysiology
Although the etiology of RSD is not yet clearly defined, several factors appear to be involved. However, the exact mechanism whereby the sympathetic response becomes abnormal is not known. Normally, an injury activates the sympathetic nervous system. Sympathetic outflow (initiated at least in part by the pain of injury) causes vasoconstriction in the limb, leading to decreased blood loss and swelling. Sympathetic tone decreases and blood flow to the limb increases, allowing ingress of the constituents of repair as well as egress of waste products from the site of injury. If sympathetic tone persists inappropriately, an abnormal feedback mechanism and an atypical sympathetic reflex result. This causes tissue edema, resulting in capillary collapse and ischemia, which in turn cause local pain in the injured limb. This pain signal re-excites the sympathetic nerves, and thus a positive feedback circuit becomes established. Both surgical and chemical sympathectomy have been recommended as means of interrupting this positive-feedback loop. 2 Sympathetic stimulation has been shown to prolong and enhance abnormal ectopic pain afferents in various experimental conditions. Experimentally produced neuromas demonstrate ectopic discharge responsive to sympathetic stimulation and hypersensitivity to chemical, mechanical, and thermal stimuli. Sympathetic stimulation normally suppresses C-fiber noci-ceptor activity. After injury, ectopically firing C fibers are stimulated by sympathetic activity. 3 Ectopic discharge has been noted in the dorsal root ganglion in experimentally produced chronic constriction of the sciatic nerve. 4 Central sensitization to increased amplitude and frequency of C-fiber nociceptor activity occurs, hardening the abnormal sympathetic reflex into an irreversible pattern. 5 Successful treatment of RSD is contingent on interruption of this abnormal continuous-feedback loop.
Recent evidence suggests a possible genetic diathesis in RSD patients resistant to treatment. Mailis and Wade 6 reported the possibility that RSD is a neuroimmune disorder linked to multiple sclerosis and narcolepsy.
Diagnosis
The diagnosis of RSD is based primarily on the patient's history and clinical characteristics. There is usually a history of recent or remote trauma, with persistent burning, aching, or throbbing pain. One or more of the following signs may be found: vasomotor or sudomotor disturbances (e.g., mottling discoloration of the extremity), edema, stiffness with loss of joint motion, sensitivity to cold, autonomic dysfunction (e.g., the limb is cold to the touch), and skin changes. Often there is muscle weakness or atrophy. Relief of pain and modification of signs after regional sympathetic blockade are virtually diagnostic of the disorder.
Many subtle cases of RSD are accompanied by only one or two of the signs and symptoms, or the entire symptom complex may be vague and confusing, making differential diagnosis difficult. Certain medical problems, such as brain injury, may make obtaining a detailed history impossible. In these cases, advanced radiologic techniques and thermography may help to confirm the diagnosis.
In addition to the physical examination, the most reliable aid to making the diagnosis of RSD is the three-phase bone scan. 7 Before the use of this modality, the finding of periarticular or diffuse mottled demineralization on plain radiographs was used. Because calcium content must be altered 30% to 50% before becoming evident on conventional radiographs, the threephase bone scan will be positive earlier than plain films will. Patchy demineralization is not specific for RSD, reportedly occurring in 30% to 80% of patients. 8 Demineralization may also result from disuse or atrophy associated with muscle paralysis. Thus, radiographs of quadriplegic or hemiplegic patients generally are not helpful in differentiating atrophy due to disuse from RSD. Spasticity in the brain-injured patient may mask or prevent the development of osteoporotic changes.
The first phase of the three-phase bone scan consists of a radionuclide angiogram (sequential 5-second images of both hands obtained over a span of 40 seconds). This is followed by a blood-pool phase involving 500,000-count images. The third-phase (delayed-phase) images are obtained 3 to 4 hours after injection. For a scan to be considered diagnostic of RSD, the delayed-phase scan must show diffusely increased activity in the involved hand and wrist joints. 7 Periarticular accentuation in the delayed phase of the three-phase bone scan has been a characteristic finding of RSD, occasionally even preceding clinical symptoms (Fig. 1) .
Mackinnon and Holder 7 have found the delayed bone-uptake phase of the three-phase bone scan to have a 96% sensitivity and a 98% specificity in detecting RSD. Using stricter criteria for the definition of RSD, Werner et al 9 found a sensitivity of 50% and a specificity of 92% for the bone-uptake phase. The sensitivity and specificity of the study were found to be higher when done within 6 months of onset and when performed on patients older than 50 years.
A positive bone scan alone does not necessarily correlate with the vascular autonomic dysfunction seen in RSD. Using cold-stress testing, Pollock et al 10 found that vasomotor response patterns to cold stress were the same whether or not a patient had a positive bone scan. O'Donoghue et al 11 found that marked asymmetry can be seen in all three phases of bone scanning in asymptomatic persons as well as in those with RSD, especially in the two early phases. At present, there is no truly reliable method to correlate bone scintigraphic findings with RSD staging or to predict outcome on the basis of the results of scanning.
Thermography has also been reported to have a role in confirming the diagnosis in the more subtle cases of RSD. Low et al 12 examined 121 patients with chronic pain and reported a 21.5% prevalence of pre- viously undiagnosed RSD. Hendler et al 13 studied patients with chronic pain for whom there was no definitive diagnosis. Nineteen percent of the patients had abnormal thermographs of the affected limb. In this subset, 74% had some clinical signs consistent with RSD. The diagnosis was then confirmed by sympathetic block. Sympathectomy was performed in some cases, which resulted in permanent pain relief.
Sylvest et al 14 have reported on the use of measurement of resting blood flow and muscle temperature as another adjunct in confirming the diagnosis of RSD. Temperature and blood flow were measured in both extremities of 51 patients, 25 of whom were believed to have RSD. The temperature of the brachioradialis muscle and the resting blood flow in the same segment of the forearm were found to be notably elevated in affected arms as compared with unaffected arms. These differences were not seen in the control group. Blood flow and muscle temperature measurements may also prove useful in assessing response to treatment.
Disease Progression and Prognosis
The course of RSD can be divided into three stages (Table 1) . Stage 1 begins immediately or shortly after injury and usually lasts 3 to 6 months. The patient has severe, diffuse, deep, burning pain of far greater severity than would be expected from the initial injury. Allodynia (extreme sensitivity to light touch) is characteristic. Pain severity may increase during stage 1, usually not following a specific dermatomal nerve pattern. Pain may be localized or regional, often spreading from its original site. Edema, initially soft and localized, spreads to include periarticular tissues, producing stiffness. Altered cutaneous blood flow regulation due to autonomic dysfunction can be manifested by erythema, pallor, or cyanosis. The affected upper extremity is held in a dystonic posture, characterized by adduction of the shoulder and flexion of the elbow, wrist, and fingers, which grows more severe with advancing disease. A fine (3-to 6-Hz) tremor is often seen in the affected extremity. 15 The tremor can often be reduced or eliminated by sympathetic block in the early phase. Trophic changes usually indicate that the condition has progressed to the second stage.
Stage 2 begins about 3 to 6 months after the onset of pain and lasts from 3 to 6 months. Pain becomes more diffuse with worsening severity. Tissue edema changes from soft to hard, with progressive joint stiffness. Vascular autonomic dysfunction continues, becoming less responsive to sympathetic blockade. Trophic changes become apparent, manifested as thin, cracked nails and thin, glossy skin with loss of flexion creases and hair.
Stage 3 starts approximately 6 to 12 months after injury and may last years or become a permanent condition. Pain reaches a plateau of severity and may show spontaneous improvement while spreading to wider areas. Pain also becomes more closely associated with movement. Fibrous ankylosis occurs as edema continues to harden. Autonomic dysfunction becomes fully stabilized, giving a constantly Reflex sympathetic dystrophy in children shows the same spectrum of clinical signs and symptoms. Wilder et al 16 followed up 70 pediatric patients with RSD. Girls predominated, and the lower extremity was affected most often. The prognosis for recovery or improvement was better in children than in adults. However, limb-length discrepancy can develop in children secondary to altered blood flow and trophic changes. 17 
Etiology Injury
Reflex sympathetic dystrophy can occur after many types of injury. Atkins et al 18 found clinical evidence of early RSD in 25% of patients with Colles' fractures 9 weeks after injury. Field et al 19 found that of 55 patients reviewed 10 years after Colles' fracture, 14 (26%) still had some residual features of RSD. Symptoms included tenderness in the fingers, persistent swelling, stiffness, and vasomotor instability. Of these 14 patients, 6 had one feature, 7 had two, and 1 had three diagnostic features of the disease.
Field et al 20 studied the association between cast tightness and the onset of RSD symptoms in patients with Colles' fractures. Pressures were measured in air bladders inserted between the cast and the forearm. Finger tenderness, joint stiffness, swelling, and vasomotor instability were considered signs of RSD. Of 23 patients, 6 (26%) showed all three features of RSD 9 weeks after fracture. These 6 patients had cast pressures greater than the 99% upper limit in the control group. The authors concluded that when intracast pressure is normal 2 weeks after fracture, it is unlikely that RSD will occur. However, an elevated intracast pressure correlated with a 60% likelihood that symptoms of RSD would develop.
Bickerstaff and Kanis 21 prospectively studied the data on 274 patients with Colles' fractures. Reflex sympathetic dystrophy, diagnosed on the basis of the presence of diffuse tenderness, vasomotor instability, swelling, and stiffness, was noted in 76 (28%). Pain, tenderness, and especially stiffness persisted in 38 (50%) of these symptomatic patients 1 year after injury. In that study, the most commonly identified risk factors for RSD were more severe fractures, fracture manipulation, and involvement of the ulnar styloid.
The association of nerve injuries, particularly multiple injuries, and RSD is well recognized. Richards 22 analyzed 461 cases of causalgia from the World War II experience and found that 382 (83%) were in patients with median or tibial nerve injury. Injury to more than one nerve occurred in 244 (53%). In 88% of nerve injuries complicated by RSD, the injury was proximal to the elbow or knee.
Partial nerve injuries are also associated with RSD, especially in the hand, which often causes an atypical presentation of RSD. This is frequently seen in patients with partial median nerve laceration, who present with classic atrophic and sudomotor changes in only the thumb, index, and long fingers while the remainder of the hand remains unaffected.
Neurologic Disorders
Nerve compression syndromes, such as carpal tunnel syndrome, cubital tunnel syndrome, and herniated cervical disk, can be complicated by RSD, with the nerve compression serving as the persistent painful stimulus. Stein 23 reported the cases of 6 patients with RSD associated with carpal tunnel syndrome. Grundberg 25 7 had diffuse hand pain, swelling, and stiffness; 4 had bilateral involvement; and 6 had bone-scan abnormalities. Three of the 6 patients with abnormal bone scans were treated with stellate ganglion blockade and improved enough to resume occupational therapy. In patients with spinal cord injuries, the bone scan pattern can be useful in differentiating pain of central origin from pain due to either unrecognized trauma or RSD.
Braus et al 26 followed up 132 hemiplegic patients following stroke. Symptoms of RSD developed in the shoulder in 27%, in most cases in the second or third month after the onset of hemiplegia. Risk factors included the presence of shoulder subluxation, marked upper-extremity weakness for at least 2 weeks after the stroke, and visual field deficit.
Weiss et al 27 prospectively studied the prognostic value of bone scanning in predicting the development of RSD after stroke. Twentytwo patients underwent threephase bone scintigraphy after stroke. Sixteen studies were con-sistent with RSD, and five of the examined extremities were symptomatic at the time of bone scanning. Of the 11 asymptomatic patients with positive scans, 7 subsequently had symptoms of RSD. No patient with a negative scan subsequently had RSD. The authors concluded that bone scintigraphy can be useful in predicting RSD in stroke patients.
Treatment
Early recognition allows prompt initiation of treatment. Therefore, a high index of suspicion is essential. Delay in treatment not only prolongs the rehabilitation period but also may allow the pain and physical alterations to become established and refractory to treatment. The most important factor in predicting improvement with treatment has been reported to be a short interval (less than 6 months) between the onset of RSD and the initiation of treatment. 28 In the authors' experience, if diagnosis is delayed until 6 months after onset, patients have a much poorer prognosis than those treated acutely or within the first 3 weeks of the onset of symptoms. Although many argue that a patient who has unremitting pain and swelling within the first 3 weeks after injury or surgery does not yet have RSD, early intervention may halt the progression of symptoms. Early treatment can include pulsed-dose corticosteroid therapy, nonsteroidal anti-inflammatory agents, analgesics for pain, and aggressive occupational or physical therapy.
Occupational and Physical Therapy
Occupational or physical therapy should be directed at maintaining active range of motion, preventing contractures by static splinting, relaxing muscle spasm, and encouraging daily compliance with the exercise program. Passive movement is not performed, thereby avoiding painful stimuli by the therapist.
Watson and Carlson 29 reported the results of use of a "stressloading" program that consisted of traction and compression exercises providing stressful stimuli to the extremity with minimal joint motion. The patients were told that specific stressful exercises were necessary to remedy their problem and that light activity or active motion alone would not work. Stress loading was used as the only form of treatment for 41 patients, many of whom had had previous treatment, including sympathetic block, range-of-motion exercises, transcutaneous electrical nerve stimulation, and splinting. At follow-up, an average of 24 months after trauma (16 months after the beginning of the stressloading program), pain scores had improved from an average of 7.7 (on a 10-point scale) before the program to 2.7. At final follow-up, 18 patients were pain-free, 18 had experienced improvement, 4 had no improvement, and 1 was worse. Over a 3-year period, 88% had lessening or relief of pain, 95% had improved range of motion, all had improved grip strength, and 84% had returned to the same occupation.
The earlier therapy is initiated, the better the prognosis. Physical therapy alone is probably more important than most drug treatments.
Drugs
Several drugs have shown promise in relieving symptoms of RSD. Of the many actions of the sympathetic nervous system, the α-adrenergic action is the most important in its effect as a vasoconstrictor in the skin and subcutaneous tissues. 2 Phenoxybenzamine is the most effective α-blocking agent and has the fewest undesirable side effects.
Ghostine et al 30 reported 40 cases of RSD after nerve injuries from missile and shrapnel wounds. Treatment was started with oral phenoxybenzamine administered in doses of 10 mg every 8 hours. The dosage was increased by 10 mg/day every 2 days until the pain was relieved or postural hypotension occurred. The maximum dose in that study was 80 mg/day. Most patients were treated for 6 weeks. In follow-up ranging from 6 months to 6 years, all 40 patients obtained complete relief.
The usual recommended starting dose for phenoxybenzamine is 10 mg/day. This dose should be maintained for at least 5 days before increase. 2 Patients treated with phenoxybenzamine must be followed up closely for postural hypotension.
Phentolamine is an alternative α-blocking agent. However, its use is contraindicated for several types of cardiac conditions; therefore, its routine use is not recommended. 2 Oral guanethidine in a single dose of 20 to 30 mg/day for 8 weeks has been suggested by Tabira et al. 31 This drug depresses the function of the postganglionic adrenergic nerves, thus blocking sympathetic nerve-mediated impulses. Disadvantages of the drug include the possibility of inciting mental depression, loss of appetite, despondency, and impotence. This drug has also been associated with orthostatic hypotension.
Mood-modifying drugs, such as chlorpromazine, chlordiazepoxide, trifluoperazine, diazepam, and amitriptyline, have been reported to be helpful in the control of RSD. 32 It should be noted that their role is only adjunctive to the primary treatment.
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Calcium channel blockers are a recent addition to the drug armamentarium for the treatment of RSD. Calcium entry blockers represent a means of inducing peripheral vasodilatation without specifically interfering with the peripheral sympathetic nervous system. This class of drugs inhibits the movement of calcium ions into cells. The resulting inhibition of excitation-contraction coupling causes relaxation of the arteriolar smooth muscle and vasodilatation. There is very little effect, however, on the smooth muscle of veins.
Nifedipine relaxes smooth muscle, increases peripheral blood flow, and antagonizes the effects of norepinephrine on arteriolar and venous smooth muscle. Nifedipine may also reverse signs of vasomotor instability and may be useful in the treatment of Raynaud's phenomenon.
Prough et al 33 reported on the use of oral nifedipine in the treatment of 13 patients with RSD. The starting dose was 10 mg three times a day. The dosage was increased weekly to a maximum of 30 mg three times a day. When a constant level of pain relief was obtained for 3 weeks, the dose was tapered over several days. Of the 13 patients, 7 had complete relief, 2 had partial relief, 3 stopped treatment because of side effects (headache), and 1 experienced no improvement.
Topical clonidine transdermal patches have been used to diminish hyperalgesia secondary to RSD. 34 A 7.0-or 10.5-cm 2 patch is used for 2 to 10 days at each site. Hyperalgesia under the patch was eliminated in the patients who had previously experienced relief from sympathetic blockade. Patients who had no relief from sympathetic blocks had no relief with topical clonidine.
Although nonsteroidal antiinflammatory drugs are commonly recommended in the treatment of the RSD patient, Wilder et al 16 found that 60% of the 70 patients in their series had no reduction in pain with this class of drugs.
Corticosteroid use in RSD remains controversial. Prednisone has been the most commonly administered corticosteroid, typically given in pulse fashion. Initially high doses are given (60 to 80 mg/day in divided doses) and then quickly tapered off. Some authors have reported good response to systemic corticosteroid therapy, but others have found no improvement. Wilder et al 16 and Braus et al 26 believe that pulsed treatment with a methylprednisolone "dosepack" is very useful in treating RSD diagnosed before a 6-month duration of symptoms, but is of limited effectiveness in cases of established disease.
Sympathetic Interruption
Sympathetic interruption can be produced chemically (either locally or regionally) or surgically. If the symptoms of RSD are not relieved promptly by oral medications and aggressive physical and occupational therapy, stellate ganglion blocks should be strongly considered. Symptomatic improvement after sympathetic blockade both confirms the diagnosis and helps to break the pain cycle.
Early in the course of disease the relief of pain may last well beyond the duration of the block and may even be curative. Initially, one or two blocks should be tried to assess effectiveness. If there is good pain relief, even temporarily, the blocks should be repeated every other day until pain is controlled, to a maximum of 12 blocks. If there is no response after two stellate ganglion blocks, surgical sympathectomy is not indicated, as this would suggest that the pain is not necessarily due to a sympathetically mediated pain syndrome. If the patient has responded to the series of 12 blocks and has recurrent pain after a short interval of relief, surgical sympathectomy is indicated.
For sympathectomy in the upper extremity, the stellate ganglion, which lies at the level of C7-T1, is bathed in either 1% lidocaine or 0.25% bupivicaine. Blocks may also be continuous.
Hobelmann and Dellon 35 used an indwelling axillary-sheath catheter to provide continuous sensory and sympathetic blockade in RSD patients during surgery for concurrent problems in the affected extremity. None of the patients experienced exacerbation of their RSD symptoms.
Linson et al 36 treated 29 RSD patients with continuous stellate blockade and vigorous physical therapy for an average of 7 days. All but 2 patients had marked relief of pain and increased range of motion. Two thirds showed improvement in trophic and vasomotor changes. Four patients achieved a normal status. Improvement was not maintained in 7 patients; of these, 6 had legal, psychiatric, or disability problems.
In a randomized, double-blind study, Hord et al 37 treated 12 patients with intravenous regional bretylium and lidocaine. Bretylium inhibits norepinephrine release by adrenergic nerve terminals. When combined with lidocaine intravenous regional block, bretylium has been found to prolong the duration of pain relief. Tourniquetproduced ischemia alone may be as effective as the intravenously injected medication. 38 Continuous blockade, while probably better than intermittent blocks, is impractical in many clinical environments. Problems with indwelling catheters include clot-ting or blockage at the tip, infection, and dislodgment of the catheter. The use of Bier block anesthesia with lidocaine and a corticosteroid or bretylium is a very effective method of treatment, with the added advantage of being able to manipulate the anesthetized extremity. Intermittent use of stellate ganglion blockade (three times per week) is also effective, particularly for patients without marked stiffness.
Recommended Treatment
A general algorithm that we have found useful in planning treatment is shown in Figure 2 . For acute onset of pain (e.g., traumatic or perioperative), we initially prescribe a methylprednisolone dosepack for 1 week; sustained-release indomethacin, 75 mg twice daily for 2 weeks; and amitriptyline, 25 mg, at bedtime. The amitriptyline is useful in treating the depression and sleep disorders commonly experienced by patients with severe pain. Elevation, ice, and aggressive occupational or physical therapy are used daily. Even after application of a cast, therapy can help prevent finger stiffness and swelling.
If improvement is found at the 1-week follow-up examination, therapy is continued three times per week until the symptoms resolve. The nonsteroidal antiinflammatory agent can be changed if necessary.
If there is no response to treatment by the end of the first week of treatment, two stellate ganglion blocks are given 2 days apart, and the methylprednisolone is continued for an additional week. If there is a good response to the stellate blocks, they are continued for 3 to 4 weeks at the rate of three per week. Patients referred with established pain patterns are initially treated with a trial of two stellate blocks. This gives both the physician and the patient a chance to better assess the cause of the pain. We then follow the same treatment protocol used for the patient with acute-onset pain. If the patient has a good response to the trial blocks, the full series of 12 blocks is given, combined with a nonsteroidal antiinflammatory medication, aggressive occupational and/or physical therapy, and amitriptyline at bedtime. The amitriptyline can be increased to 150 mg in 25 mg/week increments if necessary.
For patients with stiffness, Bier block anesthesia will allow manipulation of the joints. Bier blocks can be alternated with stellate ganglion blocks, but should probably not be used in place of the stellate blocks.
Surgical Sympathectomy
Patients with good but only temporary pain relief after sympathetic blockade may be considered for surgical sympathectomy. Using an open transthoracic or retroperitoneal approach, Olcott et al 39 reported 74% excellent, 17% good, and 9% poor results in 35 RSD patients followed up for an average of 14 months.
A new method, endoscopic surgical sympathectomy, has the potential advantage of a much shorter hospital stay. Robertson et al 40 treated eight RSD patients with video-assisted thoracic ganglionectomy. A pneumothorax was produced for the procedure, and treatment was then administered via a chest tube. The average hospital stay was 15.4 hours. Operating time was 30 minutes per side. There were no intraoperative complications. Six of the patients had complete or partial relief of their symptoms during an average followup period of 5 months. However, this procedure should not be considered benign; the senior author (H.G.) treated a patient in whom ulnar nerve resection occurred during this procedure.
Amputation
Dielissen et al 41 studied the effectiveness of amputation in relieving the symptoms of RSD in 28 patients (34 amputations in 31 limbs). Only 2 patients were relieved of pain. Reflex sympathetic dystrophy recurred in the stump in 28 limbs, so that most patients were unable to wear a prosthesis. Recurrence was most common when amputation was done through a level that was not free of symptoms. Despite the poor results in controlling pain, 24 patients were satisfied with the results of surgery. Many had considered their situation hopeless before surgery; amputation improved social function and cured persistent infection, and painful physical contact with the limb was eliminated despite the persistence of pain. Nevertheless, amputation is not recommended for pain relief because its effectiveness cannot be predicted.
Alternative Treatment Modalities
Electrical stimulation for the relief of pain has been advocated for the past century. This method fell into disrepute for a long period, but interest was renewed when Melzack and Wall 42 popularized the "gate control" theory of pain. Varying levels of success have been reported for the use of transcutaneous electrical nerve stimulation in the treatment of RSD in adults. 43 In children, however, transcutaneous nerve stimulation has been used very successfully and may be the second line of defense when physical therapy and oral medications fail to control the pain. Kesler et al 44 used physical therapy and transcutaneous nerve stimulation to treat 10 children with RSD. Seven children had complete remission within 2 months, 2 others improved, and only 1 had no response.
Electroacupuncture is rapidly gaining acceptance as a treatment alternative for patients with RSD. Chan and Chow 45 reported pain relief in 90% of patients treated. Hill et al 46 reported improvement in a small series of patients with RSD refractory to other methods of treatment, including sympathetic block. The senior author has found the improvement in response to electroacupuncture to be quite impressive, even in patients with RSD that has been refractory to other treatment modalities. Patients not only have alleviation of pain but also experience vasodilatation in the extremity, with warming and erythema. Treatments are usually done at low frequencies (less than 10 Hz) for 20 minutes.
It has been theorized that the action of electroacupuncture is in part due to the release of endorphins in the central nervous system. 47 Partial reversal of the electroacupuncture effect has been seen after subcutaneous injections of naloxone. 48 An alternative explanation may be that large-fiber transmission during acupuncture "closes the gate" to pain (according to the gate theory of Melzack and Wall 42 ). The lasting physiologic changes seen in patients with RSD after electroacupuncture appear to be caused by changes in neurovascular responses, which may arise after alterations in central nervous system neurochemistry. Electroacupuncture has the advantage of being noninvasive, with only minor, if any, side effects.
Summary
As there is no straightforward approach to the diagnosis and treatment of RSD, a high index of suspicion is critical. Because RSD is sympathetically mediated, the diagnosis can often be confirmed on the basis of the response to sympathetic blockade. Treatment may include an occupational or physical therapy program, α-adrenergic blocking agents, mood-elevating drugs, calcium channel blockers, intravenous regional blocks, and stellate ganglion blocks. Patients respond best when diagnosis is made early (within the first 2 or 3 weeks after injury) and treatment is initiated during the first stage of the disease.
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